Anagenics Limited · ASX:AN1
Anagenics — Investor Presentation (February 2024)
16 slides from Anagenics's investor presentation, Feb 7, 2024
Slide 1: Growing a portfolio of innovative health, beauty, and wellness brands
ASX: AN1 Growing a portfolio of innovative health, beauty, and wellness brands February 2024 Equity Capital Raise
Slide 2: Disclaimer
Disclaimer This presentation is dated 7 February 2024 should be read in looking statements involve known and unknown risks, or opinions contained in this presentation. conjunction with, and subject to, all information previously uncertainties, assumptions and other important factors, many of Any opi
Slide 3: Executive Summary
WHO IS ANAGENICS? Executive Summary Company ▪ Anagenics Limited (Anagenics, AN1, the Company) is a portfolio of innovative health, beauty, and Overview wellness brands aiming to grow shareholder value through M&A and profitable organic growth ▪ Several cost savings initiatives over FY23 helped to re
Slide 4: A desirable portfolio serving defined channels & markets
WHO IS ANAGENICS? A desirable portfolio serving defined channels & markets Underpinned by profitable, trusted, and validated leading brands 32 employees PARTNERSHIPS 1,110 Accounts across ANZ $14m^ USA CHINA Total revenue & other income $7m eComm sales (50% of revenue) ANZ 4 Channels of distribution
Slide 5: Right team at right time – strong operational & M&A experience
WHAT EXPERIENCE IS BEHIND ANAGENICS? Right team at right time – strong operational & M&A experience. Scott Greasley | CEO & MD M&A and transformation leader Matthew Dudek | CFO & Company Secretary Kate Hamilton | eCommerce Manager Strategic, financial and commercial experience Digital and online exp
Slide 6: Anagenics has laid the foundations for sustainable profitability
FY23 RESULTS Anagenics has laid the foundations for sustainable profitability APRIL 2023 JUNE 2023 SEPTEMBER 2023 DECEMBER 2023 H1 FY 2024 Underlying EBITDA1 improved H1 Revenue Growth +43% +16% H1 FY24 vs FY23 FY23 vs FY22 INORGANIC TALENT PROACTIVELY SOUGHT ACQUISITION CONTINUED GROWTH INTERGRATIO
Slide 7: Strategic Initiatives
FY24 AND BEYOND Strategic Initiatives Anagenics is working to accelerate: • Streamlining and simplifying its operational platform • Launching its integrated Beauty strategy • Synergistic M&A to continue redefining and leveraging cost base • Expanding new verticals in portfolio approach STREAMLINING
Slide 8: Road to Profitability
FY23 RESULTS Road to Profitability Following management restructure in FY2023, Anagenics focus has been on cost reduction and profitable sales. Progress has been slower than anticipated however the acquisitions of BLC and Face MediGroup have provided scale to reset the cost base. Given macroeconomic
Slide 9: Placement Details
ASX: AN1 Placement Details 2024 Capital Raising Presentation 9
Slide 10: Capital Raising Overview
PLACEMENT DETAILS Capital Raising Overview ▪ A two-tranche placement (“Placement Offer”) of A$1.3 million comprising: ▪ First tranche of the placement to raise up to A$0.6 million under the Company’s ASX Listing Rule 7.1 and Listing Rule 7.1A share placement capacity Offer Structure ▪ Subject to sha
Slide 11: Sources and Uses of Funds
PLACEMENT DETAILS Sources and Uses of Funds Sources of Funds (A$m) % of Total Proceeds from Placement – Tranche 1 $0.6m 48.9% Proceeds from Placement – Tranche 21 $0.7m 51.1% Total sources $1.3m 100.0% Proposed Use of Funds2 (A$m) % of Total Cost-out initiatives and integration of previous acquisiti
Slide 12: Indicative Placement Timetable
PLACEMENT TIMETABLE Indicative Placement Timetable DATE EVENT Monday, 5 February 2024 Trading halt, Announcement of two-tranche Placement Tuesday, 6 February 2024 Launch of Offer and Investor Presentation Wednesday, 7 February 2024 Announce completion of Tranche 1 of Placement and trading halt lifte
Slide 13: Pro Forma Capital Structure
PLACEMENT DETAILS Pro Forma Capital Structure Securities proposed No. of securities No. of securities % Issued share capital % to be issued in (pre-equity raising) (post-equity raising) (on an undiluted basis) Placement Offer1 Fully paid ordinary shares Hancock & Gore Ltd and associates 173,294,690
Slide 14: Key Risks
Key Risks This section discusses some of the key risks associated with any investment in Anagenics which may affect the value of its shares. The risks set out below are not listed in order of importance and do not constitute an exhaustive list of all risks involved with an investment in Anagenics. B
Slide 15: Key Risks
Key Risks SPECIFIC INVESTMENT RISKS Future capital needs and additional Anagenics’ continued ability to operate its business and effectively implement its business plan over time will depend in part on its ability to raise funds for operations and growth activities and to service, funding repay and
Slide 16: Unlock growth opportunities with Anagenics
Unlock growth opportunities with Anagenics Authorised for release to the ASX by AN1 Board of Directors Anagenics Limited Suite 204, Level 2 55 Clarence Street Sydney, NSW, 2000 Scott Greasley info@anagenics.com CEO & Managing Director anagenics.com p: +61 473 152 598 2024 EQUITY CAPITAL RAISE PRESEN